MB076
MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values <1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(-) susceptibility.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2832966-95-5
- 分子式: C9H12BN7O5S2
- 分子量:373.18
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Ki Target: ADC-7, ADC-30, ADC-162, ADC-33, ADC-219, ADC-212[1]
Ki: 0.21±0.016 μM (ADC-7), 0.058±0.005μM (ADC-30), 0.79±0.039μM (ADC-162), 0.10±0.004μM (ADC-33), 0.11±0.019 (ADC-219), 0.61±0.038μM (ADC-212)[1]
MB076 (compound B) (0.5-5 μM, 48 h) has an improved stability in human plasma[1].
MB076 (10 μg/mL, 48 h) acts synergistically in combination with Ceftazidime (CAZ, HY-B0593), and Cefotaxime (CTX, HY-A0088A) to restore pBCSK(−) susceptibility[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human Plasma
-
Concentration:0.5 μM, 1 μM, 2.5 μM, 4 μM, 5 μM
-
Incubation Time:48 h
-
Result:Showed excellent stability in human plasma, with a t1/2 value of 29 h, notably higher than the value obtained for ADC-7/S02030 (PDB4U0X) (9 h).
化学情報
-
CAS 番号 2832966-95-5
-
分子量 373.18
-
分子式 C9H12BN7O5S2
-
SMILES
NC1=NN=C(SCC(N[C@H](B(O)O)CN2C=C(C(O)=O)N=N2)=O)S1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
MB076 関連分類
HY-155011 関連分類
Powered by Bioz